Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Treatment of Acute Respiratory Failure Due to Pulmonary Embolism

Initial Management

  • The European Society of Cardiology recommends immediate anticoagulation with heparin, oxygen therapy to maintain saturation ≥90%, and risk stratification to determine the need for reperfusion therapy in high-risk patients 1, 2, 3
  • Provide supplemental oxygen to maintain target saturation of 94-98% (or 88-92% if at risk of hypercapnic respiratory failure) 4
  • Consider high-flow oxygen via nasal cannula if conventional oxygen therapy is insufficient 3, 4
  • Use non-invasive ventilation when possible before resorting to intubation 5, 4
  • If intubation becomes necessary, avoid anesthetic drugs prone to cause hypotension, use tidal volumes of approximately 6 mL/kg lean body weight, and apply positive end-expiratory pressure cautiously as it may worsen RV failure 5, 4

Anticoagulation

  • Initiate anticoagulation therapy immediately upon suspicion of PE, unless bleeding or absolute contraindications exist 1, 2
  • Prefer NOACs (Novel Oral Anticoagulants) over traditional LMWH-VKA regimen for longer-term management unless contraindicated 1, 2

Risk Stratification and Specific Management

  • Perform bedside echocardiography immediately to differentiate PE from other life-threatening conditions in high-risk patients 1, 2
  • Select appropriate reperfusion option based on patient risk profile and available resources in high-risk patients 1, 2
  • Assess RV function using imaging and laboratory biomarkers in intermediate-high risk PE patients 1, 2, 5
  • Monitor closely for signs of deterioration in intermediate-high risk PE patients 1, 2

Management of Right Ventricular Failure

  • If central venous pressure is low, consider modest fluid challenge (≤500 mL) 5
  • Avoid aggressive volume expansion as it may worsen RV function 5
  • Consider vasopressors (norepinephrine 0.2-1.0 mg/kg/min) for patients in cardiogenic shock 3, 5
  • Consider dobutamine for patients with low cardiac index but normal blood pressure 5

Special Considerations

  • Re-examine patient after 3-6 months of anticoagulation to assess benefits vs. risks of continuing treatment 2
  • Screen for persisting or new-onset dyspnea or functional limitation 2
  • Implement staged diagnostic workup if symptoms persist to exclude chronic thromboembolic pulmonary hypertension 2

Common Pitfalls

  • Delaying anticoagulation while waiting for diagnostic confirmation 1, 2
  • Excessive fluid administration worsening RV function 5
  • Failing to consider intracardiac shunting in cases of refractory hypoxemia 5
  • Missing the diagnosis of subsegmental PE (consider discussing with radiologist or seeking second opinion) 1, 2